BIOMAT Database Logo BIOMAT Database Logo

TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock. 1994

P Canale, and F Squadrito, and D Altavilla, and M Ioculano, and B Zingarelli, and G M Campo, and G Urna, and A Sardella, and G Squadrito, and A P Caputi
Institute of Pharmacology, School of Medicine, University of Messina, Italy.

The aim of this study was to evaluate: (1) the accumulation of leukocytes in the ileum and the lung during splanchnic artery occlusion (SAO) shock; (2) the role of platelet-activating factor (PAF) and tumor necrosis factor (TNF-alpha) in this phenomenon. Untreated anesthesized rats subjected to total occlusion of the celiac, superior and inferior mesenteric arteries for 45 min, followed by reperfusion, uniformly died within 90 min after reperfusion. The mean survival time was 93 +/- 7 min. The neutrophilic infiltrate was quantitated in the ileum and in the lung using a myeloperoxidase (MPO) assay. MPO activity in the ileum and in the lung averaged 0.05 +/- 0.03 and 0.4 +/- 0.02 U x 10(-3)/g protein in animals killed before occlusion. MPO activity did not change in rats killed immediately before reperfusion and was significantly elevated (0.11 +/- 0.02 and 1.7 +/- 0.6 U x 10(-3)/g protein in the ileum and the lung, respectively) in those killed 80 min after the beginning of the reperfusion. The histological examination confirmed the accumulation of leukocytes in the mucosa of the ileum and the lung over the 80 min. SAO shocked rats exhibited leukopenia and increased serum levels of TNF-alpha. In order to evaluate the role of PAF and TNF-alpha in SAO shock, a powerful PAF receptor antagonist, TCV-309 (5 micrograms/kg i.v.), was injected 5 min after reperfusion. TCV-309 increased survival time, lowered serum TNF-alpha, reduced MPO activity in both the ileum and the lung and ameliorated leukopenia induced by SAO shock.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007082 Ileum The distal and narrowest portion of the SMALL INTESTINE, between the JEJUNUM and the ILEOCECAL VALVE of the LARGE INTESTINE.
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D007962 Leukocytes White blood cells. These include granular leukocytes (BASOPHILS; EOSINOPHILS; and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES). Blood Cells, White,Blood Corpuscles, White,White Blood Cells,White Blood Corpuscles,Blood Cell, White,Blood Corpuscle, White,Corpuscle, White Blood,Corpuscles, White Blood,Leukocyte,White Blood Cell,White Blood Corpuscle
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D009195 Peroxidase A hemeprotein from leukocytes. Deficiency of this enzyme leads to a hereditary disorder coupled with disseminated moniliasis. It catalyzes the conversion of a donor and peroxide to an oxidized donor and water. EC 1.11.1.7. Myeloperoxidase,Hemi-Myeloperoxidase,Hemi Myeloperoxidase
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D010972 Platelet Activating Factor A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION. AGEPC,Acetyl Glyceryl Ether Phosphorylcholine,PAF-Acether,Phosphorylcholine, Acetyl Glyceryl Ether,1-Alkyl-2-acetyl-sn-glycerophosphocholine,Platelet Aggregating Factor,Platelet Aggregation Enhancing Factor,Platelet-Activating Substance,Thrombocyte Aggregating Activity,1 Alkyl 2 acetyl sn glycerophosphocholine,Aggregating Factor, Platelet,Factor, Platelet Activating,PAF Acether,Platelet Activating Substance
D011726 Pyridinium Compounds Derivatives of PYRIDINE containing a cation C5H5NH or radical C5H6N. Compounds, Pyridinium

Related Publications

P Canale, and F Squadrito, and D Altavilla, and M Ioculano, and B Zingarelli, and G M Campo, and G Urna, and A Sardella, and G Squadrito, and A P Caputi
Platelet-activating factor antagonist TCV-309 protects rat kidneys against ischemia-reperfusion injury.
October 1995, Transplantation proceedings,
P Canale, and F Squadrito, and D Altavilla, and M Ioculano, and B Zingarelli, and G M Campo, and G Urna, and A Sardella, and G Squadrito, and A P Caputi
Effect of TCV-309, a novel platelet activating factor antagonist, on hemodynamics in dogs with endotoxin-induced shock.
April 1995, The Journal of veterinary medical science,
P Canale, and F Squadrito, and D Altavilla, and M Ioculano, and B Zingarelli, and G M Campo, and G Urna, and A Sardella, and G Squadrito, and A P Caputi
Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
February 1992, The Journal of pharmacology and experimental therapeutics,
P Canale, and F Squadrito, and D Altavilla, and M Ioculano, and B Zingarelli, and G M Campo, and G Urna, and A Sardella, and G Squadrito, and A P Caputi
Platelet activating factor (PAF) antagonists: development of a highly potent PAF antagonist, TCV-309.
January 1991, Advances in prostaglandin, thromboxane, and leukotriene research,
P Canale, and F Squadrito, and D Altavilla, and M Ioculano, and B Zingarelli, and G M Campo, and G Urna, and A Sardella, and G Squadrito, and A P Caputi
Platelet activating factor involvement in splanchnic artery occlusion shock in rats.
January 1991, European journal of pharmacology,
P Canale, and F Squadrito, and D Altavilla, and M Ioculano, and B Zingarelli, and G M Campo, and G Urna, and A Sardella, and G Squadrito, and A P Caputi
Effect of platelet activating factor antagonist (TCV-309) on lung injury in dogs with experimentally endotoxin-induced shock.
August 1995, The Journal of veterinary medical science,
P Canale, and F Squadrito, and D Altavilla, and M Ioculano, and B Zingarelli, and G M Campo, and G Urna, and A Sardella, and G Squadrito, and A P Caputi
Beneficial effect of platelet-activating factor antagonist TCV-309 on renal ischemia-reperfusion injury.
February 1995, Transplantation proceedings,
P Canale, and F Squadrito, and D Altavilla, and M Ioculano, and B Zingarelli, and G M Campo, and G Urna, and A Sardella, and G Squadrito, and A P Caputi
Extended lung preservation with platelet-activating factor-antagonist TCV-309 in combination with prostaglandin E1.
September 1997, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
P Canale, and F Squadrito, and D Altavilla, and M Ioculano, and B Zingarelli, and G M Campo, and G Urna, and A Sardella, and G Squadrito, and A P Caputi
Effects of L-652,731, a platelet activating factor (PAF) receptor antagonist, in splanchnic artery occlusion (SAO) shock in rats.
January 1990, Pharmacological research,
P Canale, and F Squadrito, and D Altavilla, and M Ioculano, and B Zingarelli, and G M Campo, and G Urna, and A Sardella, and G Squadrito, and A P Caputi
Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock.
May 1999, British journal of pharmacology,
Copied contents to your clipboard!